Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Genet. mol. res. (Online) ; 7(2): 417-423, 2008. tab
Article in English | LILACS | ID: lil-640997

ABSTRACT

Investigation of the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in chronic myeloid leukemia patients is essential to predict prognosis and survival. In 20 patients treated at the Bone Marrow Transplantation Unit of São José do Rio Preto (São Paulo, Brazil), we used fluorescence in situ hybridization (FISH) to investigate the frequency of cells with BCR/ABL rearrangement at diagnosis and at distinct intervals after allo-HSCT until complete cytogenetic remission (CCR). We investigated the disease-free survival, overall survival in 3 years and transplant-related mortality rates, too. Bone marrow samples were collected at 1, 2, 3, 4, 6, 12, and 24 months after transplantation and additional intervals as necessary. Success rate of the FISH analyses was 100%. CCR was achieved in 75% of the patients, within on average of 3.9 months; 45% patients showed CCR within 60 days after HSCT. After 3 years of the allo-HSCT, overall survival rate was 60%, disease-free survival was 50% and the transplant-related mortality rate was 40%. The study demonstrated that the BCR-ABL FISH assay is useful for follow-up of chronic myeloid leukemia patients after HSCT and that the clinical outcome parameters in our patient cohort were similar to those described for other bone marrow transplantation units.


Subject(s)
Humans , Adolescent , Adult , Middle Aged , In Situ Hybridization, Fluorescence/methods , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Hematopoietic Stem Cell Transplantation/methods , Bone Marrow Transplantation , Brazil , Hospital Departments , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality , Prognosis , Survival Rate , Disease-Free Survival , Transplantation, Homologous , Treatment Outcome
2.
Braz. j. med. biol. res ; 37(12): 1789-1794, Dec. 2004. ilus, tab
Article in English | LILACS | ID: lil-388057

ABSTRACT

The human androgen receptor (AR) gene promoter lies in a GC-rich region containing two principal sites of transcription initiation and a putative Sp1 protein-binding site, without typical "TATA" and "CAAT" boxes. It has been suggested that mutations within the 5'untranslated region (5'UTR) may contribute to the development of prostate cancer by changing the rates of gene transcription and/or translation. In order to investigate this question, the aim of the present study was to search for the presence of mutations or polymorphisms at the AR-5'UTR in 92 prostate cancer patients, where histological diagnosis of adenocarcinoma was established in specimens obtained from transurethral resection or after prostatectomy. The AR-5'UTR was amplified by PCR from genomic DNA samples of the patients and of 100 healthy male blood donors, included as controls. Conformation-sensitive gel electrophoresis was used for DNA sequence alteration screening. Only one band shift was detected in one individual from the blood donor group. Sequencing revealed a new single nucleotide deletion (T) in the most conserved portion of the promoter region at position +36 downstream from the transcription initiation site I. Although the effect of this specific mutation remains unknown, its rarity reveals the high degree of sequence conservation of the human androgen promoter region. Moreover, the absence of detectable variation within the critical 5'UTR in prostate cancer patients indicates a low probability of its involvement in prostate cancer etiology.


Subject(s)
Humans , Male , Adolescent , Adult , Middle Aged , /genetics , Adenocarcinoma/genetics , Promoter Regions, Genetic , Prostatic Neoplasms/genetics , Receptors, Androgen/genetics , Case-Control Studies , Genetic Markers , Mutation , Polymorphism, Genetic , Sequence Analysis, DNA
3.
Braz. j. med. biol. res ; 35(2): 205-213, Feb. 2002. ilus, tab
Article in English | LILACS | ID: lil-303554

ABSTRACT

The aim of the present study was to evaluate the distribution of polymorphisms for the androgen receptor (AR) (CAG, StuI, GGN), SRD5A2 (Ala49Thr, Val89Leu) and CYP17 (MspA1) genes that are considered to be relevant for risk of prostate cancer. We studied 200 individuals from two cities in the State of Säo Paulo, by PCR, PCR-RFLP and ASOH techniques. The allelic frequencies of the autosomal markers and the StuI polymorphism of the AR gene were very similar to those described in most North American and European populations. In relation to the CAG and GGN number of repeats, the study subjects had smaller repeat lengths (mean of 20.65 and 22.38, respectively) than those described in North American, European and Chinese populations. In the present study, 30.5 percent of the individuals had less than 22 CAG repeats and 45.5 percent had less than 23 GGN repeats. When both repeat lengths are considered jointly, this Brazilian population is remarkably different from the others. Further studies on prostate cancer patients need to be conducted to assess the significance of these markers in the Brazilian population


Subject(s)
Humans , Male , Adult , Gene Frequency , Polymorphism, Genetic , Prostatic Neoplasms , Brazil , Ethnicity , Genetic Markers , Genotype , Haplotypes , Oxidoreductases , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Receptors, Androgen , Risk Factors , Steroid 17-alpha-Hydroxylase
SELECTION OF CITATIONS
SEARCH DETAIL